Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Wuxi Biologics (Cayman) (1FW2) Stock Price & Analysis

1FW2 Stock Chart & Stats

€5.13-€0.09(-1.72%)
At close: 5:30 PM GMT+1
EUR 5EUR 63 Aug17 Aug31 Aug16 Sep28 Sep13 Oct27 Oct
Day’s Range
EUR 5.13 - EUR 5.13
52-Week Range
EUR 3.21 - EUR 6.55
Previous Close
EUR 5.22
Volume
0
Average Volume (3M)
523
Market Cap
EUR 20.83B
Enterprise Value
EUR 140.19B
Total Cash (Recent Filing)
EUR 13.04B
Total Debt (Recent Filing)
EUR 2.73B
Price to Earnings (P/E)
31.2
Beta
1.16
Next Earnings
Mar 23, 2027 (Est.)
EPS Estimate
0.1
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Integrated Biologics CDMO Platform

The integrated service offering supports customers across multiple stages of biologics development, allowing Wuxi Biologics to participate beyond a single project milestone. This breadth can deepen customer relationships, create repeat opportunities as molecules advance, and support durable demand for outsourced development and manufacturing.

Strong Profitability

Healthy gross, EBIT, and net margins indicate that the company currently converts its biologics services into substantial operating and bottom-line profit. Strong profitability provides internal resources for continued investment and offers a meaningful earnings buffer as the business manages normalized margins and changing project mix.

Conservative Balance Sheet

Very low and improving leverage gives Wuxi Biologics financial flexibility to fund operations and capacity needs without relying heavily on debt. The sizeable equity base and growing assets further support resilience, while limited leverage reduces the risk that financing obligations constrain strategic choices over the next several quarters.

Bears Say

Recent Revenue Growth Slowdown

The sharp deceleration in reported revenue growth indicates that the company is not currently expanding at the pace suggested by its longer-term history. If this slower trajectory persists, it could limit operating leverage, reduce the pace of earnings growth, and make future performance more dependent on project progression and utilization.

Weak Cash Conversion

Although cash generation improved, free cash flow remains materially below accounting profit, showing that earnings are not yet converting into cash at a comparable rate. This can reduce internally available funding for expansion and leaves results more exposed to working-capital and investment requirements.

Margins Below Prior Peaks

The gap between current and peak margins suggests that profitability has normalized from exceptionally strong earlier levels. If mix or cost pressures continue, lower margins could constrain earnings growth even when revenue expands, while also reducing the operating cushion available to absorb weaker project economics.

Wuxi Biologics (Cayman) News

1FW2 FAQ

What was Wuxi Biologics (Cayman)’s price range in the past 12 months?
Wuxi Biologics (Cayman) lowest stock price was €3.21 and its highest was €6.55 in the past 12 months.
What is Wuxi Biologics (Cayman)’s market cap?
Wuxi Biologics (Cayman)’s market cap is €20.83B.
When is Wuxi Biologics (Cayman)’s upcoming earnings report date?
Wuxi Biologics (Cayman)’s next earnings report is estimated for Mar 23, 2027 (not yet confirmed), which is in 141 days.
How were Wuxi Biologics (Cayman)’s earnings last quarter?
Wuxi Biologics (Cayman) released its earnings results on Aug 25, 2026. The company reported €0.077 earnings per share for the quarter, beating the consensus estimate of €0.06 by €0.017.
Is Wuxi Biologics (Cayman) overvalued?
According to Wall Street analysts Wuxi Biologics (Cayman)’s price is currently Undervalued.
Does Wuxi Biologics (Cayman) pay dividends?
Wuxi Biologics (Cayman) does not currently pay dividends.
What is Wuxi Biologics (Cayman)’s EPS estimate?
Wuxi Biologics (Cayman)’s EPS estimate is 0.10.
How many shares outstanding does Wuxi Biologics (Cayman) have?
Wuxi Biologics (Cayman) has 4,116,762,000 shares outstanding.
What happened to Wuxi Biologics (Cayman)’s price movement after its last earnings report?
Wuxi Biologics (Cayman) reported an EPS of €0.077 in its last earnings report, beating expectations of €0.06. Following the earnings report the stock price went up 7.4%.
Which hedge fund is a major shareholder of Wuxi Biologics (Cayman)?
Currently, no hedge funds are holding shares in DE:1FW2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology